tbuckley/cabot-search huggingface dataset:
Extent of Resection and Survival in Glioblastoma Multiforme
Authors: Giovanni Grasso
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Impact of radiotherapy on pain relief and recalcification in patients affected by plasma cell neoplasms: A long-term experience.
Authors: S. Manfrida, S. Chiesa, E. Rossi, V. Frascino, G. Mantini, G. R. D'Agostino, B. De Bari, M. De Santis, V. De Stefano, M. Balducci
Journal: Journal of Clinical Oncology (2010)

e18558 Background: Solitary Plasmocytoma (SP) and Multiple Myeloma (MM) develop osteolityc bone lesions that can cause severe bone pain and pathologic fractures. This study investigated the impact of radiotherapy (RT) on pain relief and on recalcification. Methods: Patients with diagnosis of symptomatic MM and SP of bone were asked to rate their pain intensity according to a 0-10 verbal numerical rating scale (NRS) before starting radiotherapy and 2 months after irradiation. Response rate was defined according to International consensus on palliative radiotherapy criteria. Recalcification was estimated using radiological imaging at 6 months after radiotherapy and local control was defined as absence of relapse of lytic lesion on irradiated sites based on radiographic imaging. Results: From 1996 to 2007, 52 patients were treated: 42/52 (80.8%) were symptomatic MM and 10/52 ( 19.2%) were SP. Median age was 66 years (range 22-85) with a male:female ratio of 1.7:1. Irradiated sites were: spinal cord (68%), pelvic bone (12%), upper and lower extremities (9%), skull (7%) and ribs (4%). Median total dose of radiation was 38 Gy (range 16-60) delivered in a median daily fraction of 200 cGy/day (range 180-400). Forthy-five/52 (86,5%) patients presented pain before radiotherapy: severe (8≤NRS≤10) in 5/45 (11%), moderate (5≤NRS≤7) in 27/45 (60%), mild in 13/45 (29%) patients. Pain relief was obtained in 41/45 patients (91%): complete in 21 (51.2%) and partial in 20 patients (48.8%). All patients with severe pain obtained a resolution and none referred an increase of pain. Among patients with complete response, 7 (33.3%) achieved a drug reduction/suspension. Of 42 patients evaluable for recalcification, 21 (50%) obtained a radiological response, complete in 16 (38%) patients. Local control was achieved in 46/52 (88.4%) patients and, with a median follow-up of 57 months (range 21-210), 5-years local control was 80%. Conclusions: Our data confirm the effectiveness of radiotherapy on pain relief, with a reduction of drugs intake, on recalcification and support the early use of radiotherapy as part of multidiscinary approach to plasma cell neoplasms. No significant financial relationships to disclose.
Clear cell sarcoma of tendons and aponeuroses: An analysis of 75 cases
Authors: A. Kawai, R. Nakayama, A. Matsumine, S. Matsumoto, T. Ueda, H. Tsuchiya, H. Yabe, Y. Beppu
Journal: Journal of Clinical Oncology (2006)

9572 Background: Clear cell sarcoma (CCS) of tendons and aponeuroses is a rare malignant tumor that occurs most commonly in the extremities of young adults. Because of the rarity of the disease (1% of all soft tissue sarcomas), most reports about CCS have dealt with a few cases during a long time period. We conducted a multi-institutional study of CCS to clarify the clinical findings and prognostic factors of CCS treated during the era of modern multidisciplinary treatment. Methods: The records of 75 consecutive patients with histologically confirmed CCS treated at the JMOG affiliated institutions between 1980 and 2004 (follow-up; average 44 months) were reviewed. There were 41 men and 34 women with an average age of 36 years (range, 10–71 years). 65 tumors were in the extremities (foot 22, hand 13, thigh 9, others 21) and 10 were in the trunk. The tumor size ranged from 1 to 11 cm (mean, 4 cm). 52 patients presented with localized disease (M0) and 23 with metastatic disease (M1). Results: Surgical excision of the primary tumor was performed in 71 patients (limb-sparing surgery; 56, amputation; 15). Microscopic surgical margin was negative in 60 and positive in 11. 56 patients received chemotherapy (30 with measurable disease) and 17 had radiotherapy. Local recurrence occurred in 16 patients and 48 patients developed metastasis. The 5-year overall survival rate was 47% (M0; 55%, M1; 20%). On univariate analysis, sex (p=0.02), size (p=0.001), depth (p=0.002), TNM stage (p=0.001), IRS group (p=0.001) and surgical margin (p=0.04) were prognostic factors. On multivariate analysis, size (p=0.02) remained to be a significant prognostic factor. Objective response to chemotherapy was observed in 8 (27%) patients. In the group of M0 patients, those who received adjuvant chemotherapy had better prognosis (5-year survival, 65%) than those without chemotherapy (5-year survival, 23%)(p=0.03). Conclusions: The results support the contention that early diagnosis and initial excision with negative surgical margin are essential for favorable outcome of CCS. The role of chemotherapy for CCS should be further investigated. No significant financial relationships to disclose.
Analysis of clinical characteristics and outcomes of ALK positive (ALK+) patients treated with ALK inhibitors (ALKi).
Authors: Susana Cedres Perez, Nuria Pardo Aranda, Alejandro Navarro, Alex Martinez Marti, Ana Maria Martinez de Castro, Guadalupe Cabrera, Marta Vilaro, LLuisa Carbonell, Iris de la Fuente, Adelaida Piera, Lidia Martinez, Javier Hernandez-Losa, Irene Sansano, Enriqueta Felip
Journal: Journal of Clinical Oncology (2016)

e20550Background: Non-small cell lung cancer (NSCLC) harboring anaplastic lymphoid kinase (ALK) rearrangements represents a selective population who responds to targeted therapies. This study explo...
Outcomes of Open vs Laparoscopic Rectal Cancer Resection
Authors: Campbell S. Roxburgh, Jose G. Guillem
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912)
Authors: N. Fuse, H. Fukuda, Y. Yamada, A. Sawaki, W. Koizumi, Y. Suzuki, K. Yamaguchi, H. Takiuchi, A. Ohtsu, N. Boku
Journal: Journal of Clinical Oncology (2009)

4514 Background: We reported the primary results of JCOG9912 in ASCO 2007. In the planning, this study with 230 patients (pts) per arm had 80% power to demonstrate 10% superiority of CP and non-inferiority with 5% margin (HR=1.16) of S-1 at 6 months in overall survival (OS) and 0.05 study-wise 1-sided alpha. Primary analysis was conducted in Feb 2007, one year after the last patient accrual with 601 deaths (85%) of all randomized 704 pts. S-1 showed statistically significant non-inferiority to 5-FU (p&lt;0.001), but after adjusting for multiplicity either S-1 or CP failed to show statistically significant superiority to 5-FU (CP, hazard ratio (HR)=0.85 (95% CI, 0.70–1.04), p=0.055 and S-1, HR=0.83 (0.68–1.01), p=0.034). Methods: The survival information of all surviving 103 pts at the primary analysis was updated in Apr 2008 when 660 pts (94%) were dead. An updated analysis and multivariate analyses with Cox proportional hazard model were conducted. The multivariate analysis model included arms, sex, age, tumor status (unresectable/recurrent), PS, the number of metastatic sites, target lesion (TL), macroscopic type, histological type and peritoneal dissemination. Results: The updated results are shown in Table . OS curves and HRs remained almost identical to the previous report. Multivariate analyses showed that number of metastatic sites (≥2), PS (≥1), presence of TL were associated with worse survival, and that the adjusted HRs of CP and S-1 were 0.79 (0.65–0.95, p=0.014) and 0.80 (0.66–0.96, p=0.017), respectively. There was no significant interaction among baseline factors and treatment arms. Conclusions: The updated results reconfirmed the primary conclusion that S-1 monotherapy can be a new standard regimen for advanced gastric cancer, and suggest that CP is still worthy for further clinical investigation. [Table: see text] [Table: see text]
<i>The BMJ</i>appoints its first China editor
Authors: Anne Gulland
Journal: BMJ (2016)

The BMJ has appointed its first ever China editor, Daoxin Yin, a nephrologist.

Yin worked in a hospital in Beijing for five years where she developed her interest in clinical research. She then undertook a masters degree in public health at Washington University in the United States.



Daoxin Yin, nephrologist and The BMJ ’s new China editor



Her role …
Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC)
Authors: C. J. Ryan, J. Rosenberg, A. Lin, J. Valiente, J. Kim, E. J. Small
Journal: Journal of Clinical Oncology (2007)

5064 Background: Abiraterone acetate (Ab) is an oral inhibitor of 17 alpha hydroxylase and C17,20-Lyase, which are important in adrenal androgen synthesis. A phase I study was undertaken to define the maximum tolerated dose (MTD) of Ab in patients (pts) with AIPC, the need for corticosteroid replacement (CSR) and the effects of Ab on hormone levels. Methods: Eligible pts had progressive AIPC by consensus criteria and normal organ and adrenal function. Dose escalations both while fasting and with food range from 250 mg to a maximum planned dose of 2,000 mg per day. Single dose pharmacokinetic (pK) analysis was performed prior to the onset of continuous daily dosing. Results: Sixteen pts have been enrolled, 3 with non-metastatic AIPC and 13 with bone/soft tissue metastases. Median PSA and testosterone levels are 26.7 and 7.7 ng/dL, respectively. Fourteen of 16 received prior ketoconazole. CSR has been required during the first month in 1 pt at a dose level of 500 and in 1 pt in month 3. Two pts experienced syncopal events (grade 3) on Ab, one at 250 mg and one at 500 mg, both after starting CSR. Mineralocorticoid-induced hypertension (grade 2) developed in 4 pts and was treated with aldosterone antagonists. Grade 1 edema has occurred in 3 pts. Testosterone became undetectable in 4/9 pts with available data, the mineralocorticoid deoxycorticosterone rose by a median 6.7 fold on therapy (range 1.5–67 fold). PK suggest maximum concentrations of Ab are achieved within 2 hr post dose with a mean t 1/2 of 7.8 hr, and interpatient variability in AUC and Cmax of approximately 2.5 fold. A decline in PSA by &gt;50% occurred in 7 of 14 patients (50%) completing the initial 28 days of treatment. Five of 9 pts with ketoconazole refractory disease experienced a &gt;50% reduction in PSA. Conclusions: Abiraterone appears to have moderate activity in AIPC pts (including significant activity in pts treated previously with ketoconazole) and an acceptable toxicity profile. CSR has not been consistently required. No significant financial relationships to disclose.
O-0016 Cetuximab Combined with Infusional 5-Fluorouracil/Folinic Acid And Oxaliplatin in Metastatic Colorectal Cancer: Pooled Analysis of Coin and Opus Study Data
Authors: Julien Taïeb, Tim Maughan, Carsten Bokemeyer, Eric Van Cutsem, Thomas Brodowicz, Gunnar Folprecht, Regina Esser, Michael Schlichting, Josep Tabernero
Journal: Annals of Oncology (2012)
Effect of short-term cigarette smoke exposure in vitamin D deficient mice on muscle function and bone
Authors: Nele Cielen, Nele Heulens, Karen Maes, Debby Thomas, Lieselot Deleye, Liesbet Lieben, Geert Carmeliet, Marc Decramer, Wim Janssens, Ghislaine Gayan-Ramirez
Journal: American Journal of Respiratory and Critical Care Medicine (2013)
P1165 : High seroprevalence of hepatitis E in patients with autoimmune hepatitis
Authors: M. Eder, S. Beinhardt, R. Strassl, A.F. Stättermayer, C. Freissmuth, K. Kozbial, H. Holzmann, P. Ferenci, M. Trauner, H. Hofer
Journal: Journal of Hepatology (2015)
Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study
Authors: Meletios A. Dimopoulos, Martha Q Lacy, Philippe Moreau, Katja C Weisel, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Xin Yu, Lars Sternas, Christian J. Jacques, Mohamed Zaki, Jesús F San Miguel
Journal: Blood (2012)
Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.
Authors: Alice Tsang Shaw, Todd Michael Bauer, Enriqueta Felip, Benjamin Besse, Leonard Philip James, Jill S. Clancy, Ganesh Mugundu, Jean-Francois Martini, Antonello Abbattista, Benjamin J. Solomon
Journal: Journal of Clinical Oncology (2015)

8018 Background: Anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) fusions define 2 molecular subsets of patients (pts) with non-small cell lung cancer (NSCLC). PF-06463922 is a selective, brain-penetrant ALK/ROS1 tyrosine kinase inhibitor (TKI) with potent activity against de novo fusions as well as resistance mutations, including ALK G1202R, that arise during treatment with other TKIs. Methods: In an ongoing phase I portion of a phase I/II study, pts had ALK+ or ROS1+ NSCLC, with or without central nervous system (CNS) metastases, and were TKI-naïve or had disease progression after prior treatment with 1–2 TKIs. Tumor tissue (archival sample or de novo biopsy) was required for enrollment. A continual reassessment method was used to estimate the maximum tolerated dose (MTD) and identify the recommended phase II dose (RP2D). PF-06463922 was administered on day –7 and then once daily (QD) starting day 1. Primary objective was to estimate the MTD and identify a RP2D. Other objectives included efficacy, safety, pharmacokinetics (PK), effect on cognitive function, effect on cytochrome P450 (CYP) 3A4 activity, biomarkers of drug response/resistance, and intracranial antitumor activity. Results: 18 ALK+ and 4 ROS1+ pts (CNS metastases, n = 17; prior ALK TKIs, n = 19) were enrolled across 7 dose levels (10–200 mg QD). Of 15 patients evaluated for efficacy, 6 (40%) had either confirmed or unconfirmed partial responses, 5 of whom previously received 1–2 TKIs and had progression following crizotinib +/- ceritinib; intracranial responses were observed in 5 pts. Common treatment-related adverse events (AE) were hypercholesterolemia and peripheral neuropathy (23% each). The most common grade ≥ 3 treatment-related AE was hypercholesterolemia (14%). One dose-limiting toxicity occurred in a pt who received < 16 of 21 planned 200 mg QD doses due to grade 1/2 CNS effects. PK analysis showed a dose-proportional increase in exposure with a half-life of 20–28 h and moderate CYP3A4 induction. 20 pts remain on treatment. Conclusions: PF-06463922 was well tolerated and had clinical activity in pts with ALK+/ROS1+ NSCLC, most of whom had CNS metastases and received ≥ 1 prior TKI. Identification of MTD and RP2D is ongoing. Clinical trial information: NCT01970865.
A new alphabet for COPD care
Authors: Edward Kerwin
Journal: European Respiratory Journal (2016)

For 6 years, chronic obstructive pulmonary disease (COPD) specialists have struggled to discern deeper meanings in the 2011 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) A, B, C and D classification scheme [1, 2]. Now new letters, LAMA/LABA, ICS/LABA, LAMA, LABA, MABA, ICS/LAMA/LABA, SABA/SAMA (MAMMA MIA!) are dancing across the pages of COPD pharmacotherapy [3]. Combination bronchodilators improve air flow in COPD patients in trials: a defined group may benefit from ICS/LABAs <http://ow.ly/ophD302Qm5i>
Efficient derivation of microglia-like cells from human pluripotent stem cells
Authors: Julien Muffat, Yun Li, Bingbing Yuan, Maisam Mitalipova, Attya Omer, Sean Corcoran, Grisilda Bakiasi, Li-Huei Tsai, Patrick Aubourg, Richard M Ransohoff, Rudolf Jaenisch
Journal: Nature Medicine (2016)
A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy.
Authors: A. Buchner, P. Bias, M. Kaufmann
Journal: Journal of Clinical Oncology (2011)

9080 Background: XM22 is a glyco-PEGylated r-metHuG-CSF that is being developed for the reduction of duration of severe neutropenia and incidence of febrile neutropenia in cancer patients undergoing chemotherapy. Randomized, single-blind studies in healthy volunteers have evaluated the pharmacokinetics, pharmacodynamics, and safety of long-acting, subcutaneously (sc) administered XM22 in comparison to Pegfilgrastim (PEGF). The primary objective of the XM22-02-INT study was to identify the optimal fixed dose of XM22 compared to PEGF in primary breast cancer patients receiving chemotherapy (CTX). Methods: This study was a multinational, multicenter, randomized, double-blind, controlled study evaluating the efficacy and safety of fixed doses of XM22 compared to 6 mg of PEGF in breast cancer patients receiving 4 cycles of doxorubicin 60 mg/m2 and docetaxel 75 mg/m2. XM22 (3 mg, 4.5 mg, or 6 mg) or PEGF (6mg) was administered sc approximately 24 hours after CTX on each of the 4 cycles. The primary endpoint was the duration of severe neutropenia (DSN) in cycle 1. Secondary endpoints included DSN in cycles 2-4, duration and incidence of severe neutropenia, febrile neutropenia, ANC values, ANC nadir, time to ANC nadir and recovery. Pharmacokinetic parameters were also analyzed. Results: A total of 229 patients were screened and 208 randomized to XM22 3mg (n=53), XM22 4.5mg (n=51), XM22 6mg (n=50), and PEGF (n=54). Six patients did not complete the study. Demographic and baseline characteristics were comparable across the treatment groups. DSN in cycle 1 was 1.1, 0.8, 0.8, and 0.9 days in the XM22 3mg, 4.5mg, 6mg and PEGF groups, respectively. Using multivariate Poisson regression for the primary endpoint, greater efficacy was seen with higher XM22 doses. Secondary endpoints also suggested greater efficacy with increased XM22 dose. Treatment-emergent adverse events were similar between the treatment groups. Conclusions: DSN in cycle 1 was similar for all treatment groups (mean = 0.9 days), however, there was a clear trend to shorter DSN with higher XM22 doses. The study supported the use of XM22 6 mg in the phase III comparative study versus PEGF.
A randomized trial of two different genetic counseling interventions for <i>BRCA1/2</i> genetic testing
Authors: J. Garber, L. Digianni, M. Rue, K. Schneider, K. Shannon, N. Borstelmann, K. Kalkbrenner, R. Scheib
Journal: Journal of Clinical Oncology (2004)

1002 Background: We compared a randomly assigned standard genetic counseling (GC) intervention by genetic counselors versus an enhanced informed consent (EC) [modeled on routine chemotherapy informed consent] administered by oncology nurses for women enrolled into a BRCA1/2 testing program for several outcomes: satisfaction, risk perception, genetics knowledge, psychological state and health behaviors. Methods: A cohort of 236 of 310 high-risk women enrolled in a BRCA1/2 randomized control trial of semi-structured counseling interventions completed all questionnaires at enrollment, test result disclosure, 4 months and 1-year post disclosure. Women were asked about their satisfaction with the testing program at results disclosure only using the Shiloh scale; breast cancer risk perception, knowledge of cancer genetics and the Impact of Events scale at all time points. For the repeated measures, comparison was made for differences in trends over time and between the intervention arms. Exploring separately for cancer status and genetic test result, multivariate analysis of variance (MANOVA) for repeated measures was used to assess the statistical significance of the within subjects change over time and the main effects of the intervention/gene test result. Regarding satisfaction with the testing program, the Fisher's exact test was used to assess differences between intervention. Results: The overall cohort, cancer survivors, and women receiving a negative or variant BRCA1/2 result were significantly more satisfied with the GC intervention than with the EC intervention on several sub-scales. No differences were found between intervention on breast cancer risk perception or psychological state, where mutation status was significant. Contrary to expectation, knowledge of cancer genetics was not superior in the GC arm. Conclusions: Genetic counseling by genetic counselors does not prepare women better for the results of BRCA1/2 genetic testing, though women generally prefer it to a more informed consent approach to testing administered by oncology nurses within a structured program. Additional data on health behaviors will be presented. No significant financial relationships to disclose.